Abstract 473P
Background
Surgical resection (R) ± adjuvant (adj) chemotherapy (CT) is recommended for patients (pts) with stage II–IIIA NSCLC and select pts with stage IB NSCLC, however, 5-yr overall survival rates are suboptimal. ADAURA showed a survival benefit with adj osimertinib after surgery ± adj CT in pts with resected stage IB–IIIA EGFR-mutation positive (EGFRm) NSCLC; this tx is now standard of care in this setting. EGFRm NSCLC is prevalent in China; we report the proportion of pts with EGFRm NSCLC, pt demographics and tx patterns from a Chinese cohort of a global retrospective rw study prior to adj osimertinib approval.
Methods
The study population included pts ≥18 yr old, with stage IA–IIIA NSCLC who had a test for EGFR mutations (EGFRmut) and were diagnosed 01 Jan 2015–31 Dec 2020. Primary objective assessed in these pts: proportion of EGFRm NSCLC. Pts diagnosed 01 Jan 2015–31 Dec 2017, who had complete surgical R, were assessed for pt characteristics and tx patterns (primary objectives) and sites of recurrence (secondary objective) from diagnosis until 31 Dec 2020 or last follow-up/death.
Results
Of 4,636 pts, 2,248 (48%) had EGFRm NSCLC, of whom 83% had common EGFRmut; proportion of common EGFRmut did not differ by age/NSCLC stage. Proportion of EGFRm NSCLC was similar in a subgroup of 300 pts who had R (149 [50%], 85% common EGFRmut). In pts who had R, mean age was 58 yr (range 31–81), 50% were female, 65% never smokers; open lobectomy (53%) and video-assisted thoracoscopic surgery (29%) were the most common first R procedures; 56% of pts did not receive systemic tx (Table). In pts who had R, 121 (40%) had recurrence, of whom 83% had distant recurrence; most common sites of recurrence: lung (45%), bone (17%), brain (13%) and pleura (10%). Table: 473P
Treatment received, n (%) | Patients who had resection n=300 | Disease stage | ||||
IA n=131 | IB n=60 | IIA n=28 | IIB n=18 | IIIA n=63 | ||
Surgery only | 169 (56) | 112 (85) | 29 (48) | 6 (21) | 6 (33) | 16 (25) |
Surgery + (neo)adjuvant treatment* | 131 (44) | 19 (15) | 31 (52) | 22 (79) | 12 (67) | 47 (75) |
Neoadjuvant treatment + surgery + adjuvant treatment | 4 (1) | 0 | 0 | 1 (4) | 0 | 3 (5) |
Surgery + adjuvant treatment | 127 (42) | 19 (15) | 31 (52) | 21 (75) | 12 (67) | 44 (70) |
*No patients received neoadjuvant treatment only
Conclusions
Around half of Chinese pts with stage IA–IIIA NSCLC in this study had EGFRm NSCLC. Of pts who had R, the majority did not receive systemic tx; these data highlight the need for early-stage EGFR testing to optimise tx choice.
Clinical trial identification
Editorial acknowledgement
Medical writing support for the development of this abstract, under the direction of the authors, was provided by Alice Walter, BSc, of Ashfield MedComms, an Inizio company, and was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (http://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
H. Wang: Non-Financial Interests, Personal, Local PI: AstraZeneca. S. Lu: Financial Interests, Personal, Research Funding: AstraZeneca, Hutchison, BMS, Heng Rui, BeiGene, Roche, Hansoh, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Roche, Hansoh; Financial Interests, Personal, Advisory Board: Hengrui Therapeutics; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Roche. Y. Li: Non-Financial Interests, Personal, Local PI: AstraZeneca. G. Hu: Non-Financial Interests, Personal, Local PI: AstraZeneca. Q. Wang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. S. Tan: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. D. Kahangire: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract